Hybrid Drug Delivery System Designed from Spatiotemporal Hierarchical Controlled-Release Strategy Co-Delivering Rutin and Resveratrol for Coordinated Anti-Tumor Immunotherapy
Pharmaceutics · 16.07.2026 · 18 (7) · 872
DOI: 10.3390/pharmaceutics18070872 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 16.07.2026. Verfasst von Weinan Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Program for Young Talents of Basic Research in Universities of Heilongjiang Province.
Abstract (Originalsprache)
Background
The highly heterogeneous and dynamically evolving tumor microenvironment leads to the development of drug resistance and recurrence in traditional therapies. Although immunotherapy demonstrates unique advantages, its clinical utility remains constrained by the suboptimal immunogenicity and the limited effect of monotherapy. Herein, a hybrid drug delivery system based on a spatiotemporal hierarchical controlled-release strategy was proposed to achieve dual immunotherapy with immune checkpoint blockade (ICB) and immunogenic cell death (ICD) to promote synergistic anti-tumor therapy.
Methods
A liposome–micelle hybrid drug delivery system (RUT-RPP-LP) was constructed using a lipid bilayer composed of dioleoyl phosphatidylethanolamine/hemisuccinyl cholesterol to encapsulate rutin (RUT) and to form an inner cavity-encapsulated resveratrol micelle (RPP). RUT-RPP-LP was characterized, and its pH sensitivity and release behavior were investigated. Subsequently, a colon cancer tumor-bearing mouse model was constructed to evaluate the in vivo targeted anti-tumor effect and biological safety. On this basis, the combined mechanism of ICB and ICD was preliminarily explored.
Results
RUT-RPP-LP possessed excellent formulation characteristics, stability, and biocompatibility, achieving graded controlled release of drugs via responding to the TME and lysosomal acidity, respectively. Obviously, RUT-RPP-LP could specifically target the tumor site, induce the occurrence of ICD, and simultaneously block the PD-1/PD-L1 immune checkpoint signaling pathway, thereby enhancing the function of T cells and inducing apoptosis of tumor cells.
Conclusions
The RUT-RPP-LP based on the hierarchical controlled-release strategy exerted a spatiotemporally coordinated enhancement of anti-tumor immunity, and may provide a novel combinatorial approach to overcome the low response of immunotherapy in solid tumors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
- Key Laboratory of Basic and Application Research of Beiyao, Heilongjiang University of Chinese Medicine, Ministry of Education, Harbin 150040, China.
ORCID-Profile: Sisi Yan, Yanhong Wang, Zhixin Yang
Förderung
- Program for Young Talents of Basic Research in Universities of Heilongjiang Province
Zitieren
APA
Li, W., Yan, S., Gao, Y., Fu, Y., Mei, Y., Wang, Y., & Yang, Z. (2026). Hybrid Drug Delivery System Designed from Spatiotemporal Hierarchical Controlled-Release Strategy Co-Delivering Rutin and Resveratrol for Coordinated Anti-Tumor Immunotherapy. Pharmaceutics, 18(7), 872. https://doi.org/10.3390/pharmaceutics18070872
Vancouver
Li W, Yan S, Gao Y, Fu Y, Mei Y, Wang Y, et al. Hybrid Drug Delivery System Designed from Spatiotemporal Hierarchical Controlled-Release Strategy Co-Delivering Rutin and Resveratrol for Coordinated Anti-Tumor Immunotherapy. Pharmaceutics. 2026;18(7):872. doi:10.3390/pharmaceutics18070872
BibTeX
@article{Li2026,
author = {Li, Weinan and Yan, Sisi and Gao, Yingying and Fu, Yuhan and Mei, Yutong and Wang, Yanhong and Yang, Zhixin},
title = {Hybrid Drug Delivery System Designed from Spatiotemporal Hierarchical Controlled-Release Strategy Co-Delivering Rutin and Resveratrol for Coordinated Anti-Tumor Immunotherapy},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {7},
pages = {872},
doi = {10.3390/pharmaceutics18070872}
}
EUVIMED